ArticleNature2023
Hallmarks of transcriptional intratumour heterogeneity across a thousand tumours.
Abstract read
In one paragraph
Article in Nature, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 368 papers.
0numbers the graph read from it
0cells of the map it votes in
368citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
368 citing papers in PubMed.
- Motixafortide, cemiplimab, gemcitabine and nab-paclitaxel in metastatic pancreatic cancer: a single-arm phase 2 study with single-cell correlatives.Nature communications · 2026Trial
- A pilot translational study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma.Nature communications · 2026Trial
- Non-small cell lung cancer molecular subtypes and vulnerability to immunotherapy treatment combinations.Nature communications · 2025Trial
- Nivolumab plus ipilimumab induce hyper-progression in renal medullary carcinoma: results of a phase II trial and preclinical evidence.Nature communications · 2025Trial
- 4-1BBCell reports. Medicine · 2025Trial
- CDState Resolves Malignant Cell Heterogeneity from Bulk Tumor RNA Sequencing Data.Cancer research · 2026Article
- Molecular characterization of colorectal cancer liver metastases with pure desmoplastic versus non-pure desmoplastic histopathological growth patterns using a targeted gene expression panel.Clinical & experimental metastasis · 2026Article
- Clonal lineage tracing and parallel multiomics profiling reveal transcriptional heterogeneity induced by ARID1A deficiency.Science advances · 2026Article
- Article
- Decoding epithelial-mesenchymal transitions with multi-omics.Nature reviews. Genetics · 2026Review
- A TERRA-NONO axis drives fibroblast reprogramming in cancer.Science advances · 2026Article
- Integrated Genetic Screening Identifies FEN1 as a Selective Vulnerability and Temozolomide Resistance Mediator in Glioblastoma Stem Cells.Cancer research communications · 2026Article
- Integrated Multi-Omics Reveals Cellular States and Microenvironmental Remodeling in Coexisting DCIS and IDC.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Mechanistic modeling reveals a configurable AP-1 network governing cell-state heterogeneity and adaptive plasticity in melanoma cells.Cell reports · 2026Article
- scTransMIL bridges patient-level disease states and single-cell transcriptomics for cancer screening and heterogeneity inference.Nature communications · 2026Article
- Spatial analysis reveals the evolving organization of IDH-mutant glioma.Cancer cell · 2026Article
- Identification of novel paracrine therapeutic targets in peritoneal metastases through integrative proteotranscriptomic analysis of ascites.Molecular cancer · 2026Article
- A single-cell lens into the co-evolution of genotypes and phenotypes in cancer.Nature reviews. Cancer · 2026Review
- Non-coding RNA 7SK drives tumor resistance by coupling local oncogenic activation with global transcriptional repression.PLoS computational biology · 2026Article
- Identification of marginal zone B cells in head and neck cancer with immunomodulatory characteristics.Journal of advanced research · 2026Article
308 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
28 authors.
Avishai GavishDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Michael TylerDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0003-2128-5247
Alissa C GreenwaldDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Rouven HoefflinDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0002-5197-453X
Dor SimkinDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Roi TschernichovskyDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0002-3539-1940
Noam Galili DarnellDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Einav SomechDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Chaya BarbolinDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Tomer AntmanDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Daniel KovarskyDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Thomas BarrettDepartment of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, MO, USA.ORCID 0000-0002-6058-1404
L Nicolas Gonzalez CastroDepartment of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-7699-5188
Debdatta HalderDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Rony Chanoch-MyersDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Julie LaffyDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Michael MintsDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0001-9215-9518
Adi WiderDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Rotem TalDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.
Avishay SpitzerDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel.ORCID 0000-0001-6551-9338
Toshiro HaraDepartment of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.
Maria Raitses-GurevichThe Oncology Institute, Chaim Sheba Medical Center, Ramat Gan, Israel.
Chani StosselThe Oncology Institute, Chaim Sheba Medical Center, Ramat Gan, Israel.
Talia GolanThe Oncology Institute, Chaim Sheba Medical Center, Ramat Gan, Israel.
Amit TiroshThe Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel.
Mario L SuvàDepartment of Pathology and Center for Cancer Research, Massachusetts General Hospital and Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-9898-5351
Sidharth V PuramDepartment of Otolaryngology-Head and Neck Surgery, Washington University School of Medicine, St Louis, MO, USA.ORCID 0000-0003-3543-889X
Itay TiroshDepartment of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel. itay.tirosh@weizmann.ac.il.ORCID 0000-0001-5477-2987
Funding
Deciphering epigenetically-regulated pathways to improve targeted therapy for invasion and metastasis in head and neck cancerR01DE032865 · NIDCR · WASHINGTON UNIVERSITY · PI Robi D Mitra, Sidharth Venkata Puram · 2023 to 2026
$2.4MNIDCR NIH HHS R01 DE032865
Abstract
Each tumour contains diverse cellular states that underlie intratumour heterogeneity (ITH), a central challenge of cancer therapeutics
Indexed as
Gene Expression Regulation, NeoplasticGenetic HeterogeneityNeoplasmsSingle-Cell Gene Expression AnalysisEpithelial CellsHumansTumor Microenvironment
Identifiers
PMID
37258682What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.